Noninvasive Nanoscale Test Accurately Detects Bladder Cancer

Researchers have developed an accurate, noninvasive diagnostic test that can be used for a number of cancers. Their success in applying this test to the detection of bladder cancer makes it the first to effectively utilize atomic force microscopy (AFM) for diagnostic purposes. Bladder cancer is one of the most common cancers and one of the most common causes of cancer-related death. If it is detected in stage 0, bladder cancer has a five-year survival rate of 98%; if it is detected at an advance...
Continue reading

Advances in the Personalized Management of RCC With Brian I. Rini, MD, FACP

Based on recent estimates, kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States. An estimated 65,300 new cases are reported each year and more than 14,000 people die of the disease. Renal cell carcinoma (RCC), which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. As a result of its often asymptomatic presentation, many patients present ...
Continue reading

BAP1 Promotes Tumor Suppression Via Ferroptosis

Research performed at The University of Texas MD Anderson Cancer Center shows a potential new area of cancer therapy through the examination of BRCA-associated protein 1 (BAP1), a tumor suppressor gene in kidney, eye, bile duct, mesothelioma, and other cancers. BAP1 encodes a key enzyme which results in a type of cell death called ferroptosis. The team, led by Boyi Gan, PhD, associate professor at the Department of Experimental Radiation Oncology, identified a BAP1-mediated epigenetic mechanism ...
Continue reading

Kidney Cancer: CT Scan Enhancement Avoids Unneeded Surgery

In a new study published in Clinical Cancer Research,  researchers have found a radiographic measure that can differentiate a benign type of kidney tumor from a potentially deadly one, eliminating the need for unnecessary surgeries. According to senior author Eric Kauffman, MD, assistant professor of oncology at Roswell Park Comprehensive Cancer Center, kidney tumors are unusual in that a biopsy cannot always confirm whether they are cancerous or benign. Tumor biopsies that test positive fo...
Continue reading

Expanding Range of Biomarkers for Immune Checkpoint Therapy

Recent research conducted at the Dana-Farber Cancer Institute and published in Nature Genetics has provided new biomarkers for predicting the efficacy of immune checkpoint inhibitors. Despite existing knowledge of biomarkers such as tumor mutational burden and wide clinical success across many cancer types, oncologists still face difficulty in gauging which patients will respond to immune checkpoint inhibitors and which will show resistance. Previous studies that sought to explore additional bio...
Continue reading
© Copyright 2018 i3 Health. All rights reserved.